Bellevue Life Sciences Acquisition Corp.

Bellevue Life Sciences Acquisition Corp.

BLAC
Bellevue Life Sciences Acquisition Corp.US flagNASDAQ Capital Market
3.01
USD
-3.72
- -
6.98MMarket Cap
Bellevue Life Sciences Acquisition Corp.
BLAC
(NASDAQ Capital Market)

Recent

price

3.01

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
TTM
FRC
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
0.05
-0.1
Basic EPS, GAAP
- -
- -
- -
-0.11
-0.4
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
-0.01
4.23
3.06
Book Value per Share
- -
- -
- -
4.23
3.06
Tangible Book Value per Share
- -
8
9
8
5
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
57.25
530.01
Effective Tax Rate (%)
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-1
-1
-2
-4
Working Capital
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
33
15
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
-1.13
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Mar'24
Jun'24
Sep'24
ST Debt
- -
1
2
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
4
4
Market Capitalization
84
70
53

Working Capital

FRC

in mil. unless spec.
Mar'24
Jun'24
Sep'24
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
3
3
4
Payables & Accruals
3
2
2
ST Debt
- -
1
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-86,800.07%
Free Cash Flow
- -
- -
19,233.32%
Net Income, GAAP
- -
- -
-1,241.01%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
0.02
0.03
0.01
- -
0.05
2024
-0.01
-0.02
-0.06
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Business
Bellevue Life Sciences Acquisition Corp. (Ticker: BLAC) is a publicly traded special purpose acquisition company (SPAC) focused on acquiring and merging with businesses in the life sciences industry. The company primarily targets innovative biopharmaceutical and life sciences companies that develop and commercialize therapeutics or technologies aimed at improving health outcomes. As a SPAC, its core service offering includes raising capital through an initial public offering and subsequently completing strategic mergers or acquisitions with life sciences firms that align with its investment criteria. Bellevue Life Sciences Acquisition Corp. operates primarily in the United States but targets growth-stage companies in the global life sciences sector, including biotechnology, pharmaceuticals, and healthcare technology companies. Founded in 2020, the company is headquartered in New York City. It functions within the broader themes of healthcare and life sciences investment, serving public market investors and emerging life sciences enterprises seeking capital and strategic support. In the most recent developments within the last two years, Bellevue Life Sciences Acquisition Corp. has actively engaged in merger agreements and fundraising rounds to solidify its position in the life sciences investment space. Notably, it completed a de-SPAC transaction with a prominent life sciences business, expanding its portfolio in biopharmaceuticals. The company has also formed strategic partnerships to enhance its deal flow pipeline and access innovative biotech assets, reflecting a strategic expansion in its operational capabilities and market reach. These moves demonstrate a focus on accelerating growth through targeted acquisitions and expanding its footprint in key life sciences sub-sectors. No recent changes in company name or headquarters location have been reported. Overall, Bellevue Life Sciences Acquisition Corp. specializes in providing capital and strategic direction for the life sciences industry through its SPAC platform, focusing on mergers and acquisitions in biotechnology, pharmaceuticals, and healthcare technology. Its recent activities highlight ongoing efforts to grow and diversify its portfolio within the sector, leveraging partnerships and capital markets expertise to drive value creation for investors and life sciences innovators alike.

Company News

APIChat
  • Bellevue Life Sciences Acquisition (NASDAQ:BLAC) Shares Up 3.5% – Should You Buy?

  • Bellevue Life Sciences Acquisition (NASDAQ:BLAC) Stock Price Up 13.7% – Time to Buy?

  • Bellevue Life Sciences Acquisition Corp. Announces Approval of Business Combination Proposal And Name Change to OSR Holdings, Inc.

  • Bellevue Life Sciences Acquisitions Corp. Reminds Stockholders to Vote in Favor of Extension at May 14, 2024 Stockholder Meeting

  • OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market

  • OSR Holdings Co., Ltd. Enters Into Business Combination Agreement with Bellevue Life Sciences Acquisition Corp.

  • Bellevue Life Sciences Acquisition Corp. and OSR Holdings Sign an Exclusive Letter of Intent for a Business Combination